Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-411-2 | CAS number: 95-33-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
- In vivo carcinogenicity study in the mouse: not carcinogenic B6C3F1 strains and the B6AK1 strains of mouse at dose level corresponding to a time weight average dose of 95.3 mg/kg bw and day.(NCI 1968, Key/Sup, Rel.2).
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- acceptable well-documented publication, which meets basic scientific principles (This long-term carcinogenicity study is not in accordance with current testing procedures as proposed by guidelines on carcinogenicity and/or combined chronic toxicity carcinogenicity. However, this study is performed in accordance with generally accepted scientific standards.)
- Principles of method if other than guideline:
- In a carcinogenicity study in B6C3F1 and B6AKF1 mice (each 18 males and 18 females) received a continuous daily oral application by stomach tube from 7th day of age until the mice were at weanling age (28 days) following which the compound was mixed with the ground feed for 18 month in total.
- GLP compliance:
- no
- Species:
- mouse
- Strain:
- other: B6C3F1 and B6AKF1
- Sex:
- male/female
- Route of administration:
- oral: unspecified
- Vehicle:
- other: 0.5% gelatin
- Duration of treatment / exposure:
- 18 months
- Frequency of treatment:
- daily
- Remarks:
- Doses / Concentrations:
7th to 28th day of age: 215 mg/kg bw/d by stomach tube, thereafter administration of 692 mg/kg diet (appr. 95.3 mg/kg bw/d according to EU risk assessment 2007). - No. of animals per sex per dose:
- 18 per dose and sex
- Control animals:
- yes
- Details on study design:
- Post-exposure period: no
- Key result
- Dose descriptor:
- dose level: Surviving and tumors
- Effect level:
- ca. 95.3 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: No statistically significant differences between CBS-treated and control mice in the incidence of the individual types of tumors
- Key result
- Critical effects observed:
- no
- Conclusions:
- No adverse effects reported.
- Executive summary:
Groups of 18 mice per sex of the B6C3F1 strains and the B6AK1 strains, were given 215 mg/kg bw and day CBS by repeated oral gavage for 21 days followed by exposure for nearly 17 months to diet containing CBS at a concentration equivalent to ca. 90 mg/kg bw/d (corresponding to a time weight average dose of 95.3 mg/kg bw and day. An equal number of mice served as vehicle control. Survival of the CBS-treated mice of both strains was comparable to the control group (vehicle control B6C3F1: male 16/18, females 16/18; B6AKF1 male: 18/18, female: 15/18; CBS treated B6C3F1 mice: male 16/18, females: 15/18; B6AKF1 male: 18/18, female: 17/18. No adverse effects were reported. Tumours were found in all groups but there were no statistically significant differences between CBS-treated and control mice in the incidence of the individual types of tumour. The total number of tumours was not statistically significant different in CBS-treated and control mice (vehicle control B6C3F1 mice male/female: 3/4, B6AKF1 mice male/female: 3/3; CBS treated B6C3F1 mice male/female: 8/6, CBS treated B6AKF1 mice male/female: 3/3). In summary there was no evidence of a carcinogenic effect in both strains of mice (NCI 1968).
Reference
Mice surviving 18 months:
Gelatin Control: B6C3F1 mice:(m:16/18, f: 16/18), B6AKF1 mice: (m:18/18, f: 15/18).
Treatment group:B6C3F1 mice: (m: 16/18; f: 15/18), B6AKF1 mice: (m:18/18, f: 17/18).
No adverse effects reported.
Tumors were found in all groups but there were no statistically significant differences between CBS-treated mice and controls.The total number of tumors were not statistically significant different from CBS-treated and control mice.
Total number of tumors:
Gelalatin control:B6C3F1 mice: (m:3; f: 4), B6AKF1 mice: (m: 3, f:3).
Treatment group:B6C3F1 mice: (m: 8, f: 6), B6AKF1 mice: (m:3/3).
No increased tumor incidence.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 95.3 mg/kg bw/day
- Study duration:
- chronic
- Species:
- mouse
- Quality of whole database:
- Study was performed in accordance with generally accepted scientific standard.
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified.
Additional information
Carcinogenicity: oral
Groups of 18 mice per sex of the B6C3F1 strains and the B6AK1 strains, were given 215 mg/kg bw and day CBS by repeated oral gavage for 21 days followed by exposure for nearly 17 months to diet containing CBS at a concentration equivalent to ca. 90 mg/kg bw/d (corresponding to a time weight average dose of 95.3 mg/kg bw and day. An equal number of mice served as vehicle control. Survival of the CBS-treated mice of both strains was comparable to the control group (vehicle control B6C3F1: male 16/18, females 16/18; B6AKF1 male: 18/18, female: 15/18; CBS treated B6C3F1 mice: male 16/18, females: 15/18; B6AKF1 male: 18/18, female: 17/18. No adverse effects were reported. Tumors were found in all groups but there were no statistically significant differences between CBS-treated and control mice in the incidence of the individual types of tumor. The total number of tumors was not statistically significant different in CBS-treated and control mice (vehicle control B6C3F1 mice male/female: 3/4, B6AKF1 mice male/female: 3/3; CBS treated B6C3F1 mice male/female: 8/6, CBS treated B6AKF1 mice male/female: 3/3). In summary there was no evidence of a carcinogenic effect in both strains of mice (NCI 1968).
Carcinogenicity: other route (dermal)
Groups of 18 B6C3F1 and 18 B6AKF1 mice of each sex received a single subcutaneous injection in 0.05 ml suspension (1000 mg/kg) CBS in the nape of the neck with sacrifice at ca. 17 months after injection (no more data available). An equal number of mice of each strain served as vehicle control. Survival of the CBS-treated mice was comparable to the control group in both strains. No adverse effects were reported and no statistically increase in tumor incidences were observed in mice of both strains. The total number was similar in treated and control mice (vehicle control B6C3F1 male/female mice: 4/0, B6AKF1mice male/female: 1/1; CBS treated B6C3F1 mice male/female: 3/1, CBS B6AKF1 mice male and female 0/2). In summary there was no evidence of a carcinogenic effect of CBS in both strains of mice (NCI 1968).
The metabolite 2-Mercaptobenzothiazole (MBT) is the relevant and common metabolite for all category members (CBS, TBBS, MDS and DCBS), data on 2-Mercaptobenzothiazole (MBT) CAS No. 149-30-4, EC no. 205-736-8 are also relevant for consideration of the carcinogenic potential of the category of substances. Refer to section 13.2 for the statement of carcinogenic potential of 2-Mercaptobenzothiazole (MBT) for more information.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.